UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017366
Receipt number R000020152
Scientific Title Comparison of iron supplementation methods for hemodialysis patients
Date of disclosure of the study information 2015/05/01
Last modified on 2018/05/31 12:26:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of iron supplementation methods for hemodialysis patients

Acronym

Comparison of iron supplementation methods for hemodialysis patients

Scientific Title

Comparison of iron supplementation methods for hemodialysis patients

Scientific Title:Acronym

Comparison of iron supplementation methods for hemodialysis patients

Region

Japan


Condition

Condition

end-stage kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the efficacy and safety of intravenous and oral iron supplementation in hemodialysis patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in hemoglobin values of before and after the iron supplementation and the frequency of side effect by iron supplementation

Key secondary outcomes

Changes in values of serum iron, transferrin saturation, ferritin, and the amount of administered erythropoiesis-stimulating agents


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Intravenous administration of 40mg of saccharated ferric oxide once a week after hemodialysis

Interventions/Control_2

Oral administration of 50-100mg of sodium ferrous citrate per day

Interventions/Control_3

Ferric citrate hydrate group: oral administration of 500-2250mg of ferric citrate hydrate per day irrespective of iron deficiency [In this group, only patients with hyperphosphatemia (serum phosphate >6.0mg/dL) are registered.]

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Hemodialysis patients complicated with iron deficiency (transferrin saturation < 20% and ferritin < 100 ng/mL) or hyperphosphatemia

Key exclusion criteria

Patients complicated with potential diseases causing anemia such as hemorrhagic disease, hematological disease, or carcinoma

Target sample size

300


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Michio Kuwahara

Organization

Shuuwa General Hospital

Division name

Department of Nephrology

Zip code


Address

1200 Yahara-Shinden, Kasukabe, Saitama 344-0035, Japan

TEL

048-737-2121

Email

kuwaharam@shuuwa-gh.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Michio Kuwahara

Organization

Shuuwa General Hospital

Division name

Department of Nephrology

Zip code


Address

1200 Yahara-Shinden, Kasukabe, Saitama 344-0035, Japan

TEL

048-737-2121

Homepage URL


Email

kuwaharam@shuuwa-gh.or.jp


Sponsor or person

Institute

Shuuwa General Hospital

Institute

Department

Personal name



Funding Source

Organization

Shuuwa General Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 10 Month 27 Day

Date of IRB


Anticipated trial start date

2014 Year 11 Month 04 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This research had been planned and promoted by Michio Kuwahara (MK). However, MK was transferred to work in April 2017, and MK currently work for another hospital.
MK wss unable to find a researcher who will take over this research. Therefore, MK had to abandon the continuation of this research.


Management information

Registered date

2015 Year 05 Month 01 Day

Last modified on

2018 Year 05 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020152


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name